$AGEN
AGENUS INC
Runway:3 mo
NasdaqMarket cap: —CIK 0001098972
Upcoming catalysts
1 surfacedDrug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05529316 | Botensilimab | Phase 2 | Active Not Recruiting | 2028-02-01 |
| NCT05608044 | Botensilimab | Phase 2 | Active Not Recruiting | 2027-09-01 |
| NCT05630183 | Botensilimab | Phase 2 | Active Not Recruiting | 2025-12-05 |
| NCT03894215 | AGEN2034 | Phase 2 | Terminated | 2025-03-26 |
| NCT03860272 | Botensilimab | Phase 1 | Active Not Recruiting | 2025-01-13 |
| NCT05033132 | Balstilimab (BAL) | Phase 2 | Withdrawn | 2024-12-30 |
| NCT05377528 | AGEN1571 | Phase 1 | Completed | 2024-12-23 |
| NCT04121676 | AGEN2373 | Phase 1 | Completed | 2024-02-22 |
| NCT05025085 | AGEN1777 | Phase 1 | Completed | 2023-07-11 |
| NCT03495882 | AGEN1884 + AGEN2034 | Phase 2 | Completed | 2022-07-15 |
| NCT03104699 | AGEN2034 | Phase 2 | Completed | 2022-06-15 |
| NCT02694822 | Zalifrelimab | Phase 2 | Completed | 2022-03-30 |
| NCT04943627 | Balstilimab (BAL) | Phase 3 | Withdrawn | 2021-10-22 |
| NCT04607200 | AGEN2034 | Phase 2 | Withdrawn | 2021-09-13 |
| NCT04156100 | AGEN1223 | Phase 1 | Terminated | 2021-04-08 |
| NCT03673020 | ASV® AGEN2017 + QS-21 Stimulon® adjuvant | Phase 1 | Completed | 2021-02-03 |
| NCT02992977 | AutoSynVax™ vaccine | Phase 1 | Terminated | 2018-12-01 |
| NCT03411473 | AGEN1884 in combination with pembrolizumab | Phase 2 | Terminated | 2018-05-01 |
| NCT01687595 | HerpV and QS-21 | Phase 2 | Completed | 2013-09-01 |
| NCT01147536 | HSPPC-96 | Phase 2 | Terminated | 2012-06-01 |